Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Accumulated Depreciation (2019 - 2022)

Avidity Biosciences' Accumulated Depreciation history spans 4 years, with the latest figure at $2.7 million for Q3 2022.

  • For Q3 2022, Accumulated Depreciation rose 38.54% year-over-year to $2.7 million; the TTM value through Sep 2022 reached $2.7 million, up 38.54%, while the annual FY2021 figure was $1.7 million, 12.43% down from the prior year.
  • Accumulated Depreciation reached $2.7 million in Q3 2022 per RNA's latest filing, up from $2.4 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $2.7 million in Q3 2022 to a low of $1.6 million in Q4 2019.
  • Average Accumulated Depreciation over 4 years is $2.0 million, with a median of $1.9 million recorded in 2020.
  • Peak YoY movement for Accumulated Depreciation: dropped 12.43% in 2021, then surged 38.54% in 2022.
  • A 4-year view of Accumulated Depreciation shows it stood at $1.6 million in 2019, then rose by 20.45% to $2.0 million in 2020, then decreased by 12.43% to $1.7 million in 2021, then soared by 58.05% to $2.7 million in 2022.
  • Per Business Quant, the three most recent readings for RNA's Accumulated Depreciation are $2.7 million (Q3 2022), $2.4 million (Q2 2022), and $2.0 million (Q1 2022).